Cedoroxim
(Cefuroxime Axetil 500mg Tablets)
(Cefuroxime Sodium 1.5gm Vial )
| INFECTIONS | DOSAGE & DURATION | |
|---|---|---|
| TABLET | INJECTION | |
| Upper & Lower Respiratory Tract Infections | 250-500 mg BID; 5-10 days | mg TID: 5-10 days |
| Uncomplicated & Complicated Skin and Skin-Structure Infections | 250-500 mg BID; 10 days | 750 mg TID; 5-10 days. |
| Uncomplicated Urinary Tract Infections | 250 mg BID; 7-10 days | 750 mg TID; 5-10 days |
| Uncomplicated Gonorrhea | 1,000 mg Once; Single Dose | 750 mg TID: 5-10 days |
| Severe or Complicated Infections | -- | 1.5 gm TID |
| Bone and Joint Infections | -- | 1.5 gm TID |
| Meningitis | -- | Should not exceed 3 gm TID |
| Life-threatening Infections or Infections due to less susceptible organisms | -- | 1.5 gm QID |
| Preventive use for clean-contaminated or potentially contaminated Surgical Procedures | -- | 1.5gm dose administered IV just before surgery (approx. one-half to 1 hr before the initial incision) is recommended. Thereafter, give 750 mg IV TID when the procedure is prolonged. |
| Preventive use during Open Heart Surgery | -- | 1.5 gm dose administered IV at the induction of anesthesia and every 12 hrs thereafter for a total of 6 gm is recommended |
An updated review of its use in the management of bacterial infections
- Cefuroxime axetil is a broad spectrum antibacterial agent with a pharmacokinetic profile that permits convenient twice-daily administration.
- Drug is an effective and well tolerated treatment in patients with various infections including Otitis Media, Pharyngitis, Sinusitis, CAP and Acute Exacerbations of Chronic Bronchitis,
- Cefuroxime axetil may be considered as an empirical therapy for a range of Community - Acquired Infections, including those in which Blactamase producing strains of common respiratory pathogens are identified as the causative organisms.
- In an era of rapidly emerging bacterial resistance, empirical treatment with bacterial agents, potentially preventing the emergence of bacterial resistance to agents such as Cefuroxime Axetil may ensure the appropriate use of newer antibacterial agents, potentially preventing the emergence of bacterial resistance to these newer drugs.
